Juvenile Idiopathic Arthritis Diagnostic Market Snapshot (2022 to 2032)
Global juvenile idiopathic arthritis diagnostic market demand is anticipated to be valued at US$ 5,810.5 Million in 2022, forecast to grow at a CAGR of 4.0% to be valued at US$ 8,600.7 Million from 2022 to 2032. Growth is attributed to the increasing prevalence of diseases such as Oligoarthritis, Polyarticular arthritis, rheumatoid factor negative, Psoriatic arthritis, and Enthesitis-related arthritis.
Report Attribute
Details
Estimated Base Year Value (2021)
US$ 5,795.5 Million
Expected Market Value (2022)
US$ 5,810.5 Million
Anticipated Forecast Value (2032)
US$ 8,600.7 Million
Projected Growth Rate (2022 to 2032)
4.0% CAGR
Juvenile idiopathic arthritis is a disease that causes pain and inflammation in joints with the common symptom of musculoskeletal pain. Juvenile idiopathic arthritis or juvenile rheumatoid arthritis is the common inflammatory arthritis of childhood and mostly affects the under 17 age group children.
The USA is considered to be a highly lucrative market for juvenile idiopathic arthritis diagnosis due to the presence of the technologically advanced healthcare and pharmaceutical industry.
Government initiatives regarding awareness of Juvenile Idiopathic Arthritis disease are likely to drive the growth of the Juvenile Idiopathic Arthritis Diagnostics market. Additionally, the increasing incidence of chronic arthritis is expected to boost the juvenile idiopathic arthritis diagnostic market over the forecast period. Rising awareness among the general population and a better understanding of these drugs is expected to drive the juvenile idiopathic arthritis diagnostic market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers Spearheading Juvenile Idiopathic Arthritis Diagnostic Market Growth?
The juvenile idiopathic arthritis diagnostic market is expected to grow in the coming forecast period for increasing demand for more effective drugs and better medical facilities. The major factor that will propel the growth of the juvenile idiopathic arthritis diagnostic market is the rising focus by the manufacturer to develop tests creating huge opportunities for patients.
The growth of the healthcare industry is expected to be one of the primary factors driving the diagnostic lab market which in turn is expected to augment the demand for the Juvenile Idiopathic Arthritis diagnostic market over the next few years. In addition, rapid Research and Development activities are expected to fuel the demand for the market over the forecasting period. The research laboratory is expected to accrue significant benefits to the global juvenile idiopathic arthritis diagnostic market.
What are the Challenges Faced by the Juvenile Idiopathic Arthritis Diagnostic Industry?
Although the juvenile idiopathic arthritis diagnostic market has numerous end-uses, there are numerous obstacles likely to pose a challenge to market growth. The high cost of treatment of juvenile arthritis is expected to hinder the growth of the juvenile idiopathic arthritis diagnostic market.
Lack of awareness and less expenditure spent on healthcare and research may restrain the growth of the Juvenile Idiopathic Arthritis Diagnostics market. Difficult diagnostic procedures and limited availability of tests may restrain the growth of the Juvenile Idiopathic Arthritis Diagnostics market in the forecasting period.
Find your sweet spots for generating winning opportunities in this market.
Why is North America Emerging as an Opportunistic Juvenile Idiopathic Arthritis Diagnostic Market?
North America has the largest market for juvenile idiopathic arthritis diagnostics and the trend is expected to continue into the forecast period owing to a rapid increase in healthcare expenditure and increasing research and development activities in the region. The region is forecast to surge at over 3.7% CAGR from 2022 to 2032.
The rising prevalence of chronic arthritis is expected to drive the growth of the juvenile idiopathic Arthritis Diagnostic Market over the forecast period. Increasing awareness among the general population, the significance of this condition, and a better understanding of these drugs are expected to drive the juvenile idiopathic arthritis diagnostic market during the forecast period.
How is Europe Contributing to the Growth of the Juvenile Idiopathic Arthritis Diagnostic Market?
According to Future Market Insights, Europe is expected to provide immense growth opportunities for the juvenile idiopathic arthritis diagnostic market. Higher spending on healthcare expenditure is keeping sales of the juvenile idiopathic arthritis diagnostic market afloat across the United Kingdom.
Increasing research and development activities, the development of drugs for the treatment of polyarticular juvenile idiopathic arthritis, and higher demand from the end-users provide growth opportunities to the market in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Market Competition
Some of the key participants present in the global juvenile idiopathic arthritis diagnostic market include Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, Zydus Cadila, Genentech, Inc., and Latona Life Sciences among others.
Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as A Johnson & Johnson Services, Inc., and Novartis International AG account for a considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 4.0% from 2022 to 2032
Market Value in 2022
US$ 5,810.5 Million
Market Value in 2032
US$ 8,600.7 Million
Base Year for Estimation
2021
Historical Data
2017 to 2021
Forecast Period
2022 to 2032
Quantitative Units
Revenue in USD Billion, Volume in Kilotons, and CAGR from 2022 to 2032
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Disease Indication
End-user
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
United Kingdom
France
Italy
BENELUX
Russia
China
Japan
South Korea
South Africa
GCC Countries
South Africa
Turkey
Key Companies Profiled
Johnson & Johnson Services Inc.
Novartis International AG
Bristol-Myers Squibb
Zydus Cadila
Genentech Inc.
Latona Life Sciences
Customization
Available Upon Request
Key Segments Profiled in the Juvenile Idiopathic Arthritis Diagnostic Industry Survey
By Disease Indication:
Blood Tests
ESR
C-Reactive Protein
Anti-Nuclear Antibody
Rheumatoid Factor
Cyclic Citrullinated Peptide (CCP)
HLA-B27 Tests
Imaging Scans
X-rays
MRI
By End-User:
Hospitals
Research Laboratories
Laboratories
Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
What is the anticipated growth of the juvenile idiopathic arthritis diagnostic until 2032?
FMI projects the global juvenile idiopathic arthritis diagnostic market to expand at a 4.0% value CAGR by 2032
Which region is forecast to be the most lucrative for juvenile idiopathic arthritis diagnostic market growth?
North America is expected to be the most opportunistic juvenile idiopathic arthritis diagnostic market, expanding at a 3.7% CAGR
Which are some prominent juvenile idiopathic arthritis diagnostic manufacturers?
Johnson & Johnson Services, Inc., Novartis International AG, Bristol-Myers Squibb, and Zydus Cadila are some prominent juvenile idiopathic arthritis diagnostic market manufacturers
Table of Content
1. Executive Summary | Juvenile Idiopathic Arthritis Diagnostic Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2022 to 2032
5.3.1. Blood Tests
5.3.2. ESR
5.3.3. C-reactive Protein
5.3.4. Anti-nuclear Antibody
5.3.5. Rheumatoid Factor
5.3.6. Cyclic Citrullinated Peptide (CCP)
5.3.7. HLA-B27 Tests
5.3.8. Imaging Scans
5.3.9. X-rays
5.3.10. MRI
5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Disease Indication, 2022 to 2032
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032
6.3.1. Hospitals
6.3.2. Research Laboratories
6.3.3. Diagnostic Laboratories
6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Disease Indication
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Disease Indication
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Disease Indication
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Indication
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. United Kingdom
10.2.1.5. Russia
10.2.1.6. BENELUX
10.2.1.7. Rest of Europe
10.2.2. By Disease Indication
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Indication
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Rest of Asia Pacific
11.2.2. By Disease Indication
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Indication
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Turkey
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Disease Indication
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Indication
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Disease Indication
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Disease Indication
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Disease Indication
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Disease Indication
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Disease Indication
13.5.2.2. By End User
13.6. Italy
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Disease Indication
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Disease Indication
13.7.2.2. By End User
13.8. United Kingdom
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Disease Indication
13.8.2.2. By End User
13.9. Russia
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Disease Indication
13.9.2.2. By End User
13.10. BENELUX
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Disease Indication
13.10.2.2. By End User
13.11. China
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Disease Indication
13.11.2.2. By End User
13.12. Japan
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Disease Indication
13.12.2.2. By End User
13.13. South Korea
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Disease Indication
13.13.2.2. By End User
13.14. GCC Countries
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Disease Indication
13.14.2.2. By End User
13.15. South Africa
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Disease Indication
13.15.2.2. By End User
13.16. Turkey
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2021
13.16.2.1. By Disease Indication
13.16.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Disease Indication
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Johnson & Johnson Services
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Novartis International AG
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Bristol-Myers Squibb
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Zydus Cadila
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Genentech
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Latona Life Sciences
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
16. Assumptions & Acronyms Used17. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 4: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 5: North America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 6: North America Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 8: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 11: Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 12: Europe Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End User, 2017 to 2032
Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032
Table 18: Middle East and Africa Market Value (US$ Million) Forecast by End User, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by End User, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 7: Global Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 8: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 9: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 10: Global Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 13: Global Market Attractiveness by Disease Indication, 2022 to 2032
Figure 14: Global Market Attractiveness by End User, 2022 to 2032
Figure 15: Global Market Attractiveness by Region, 2022 to 2032
Figure 16: North America Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 17: North America Market Value (US$ Million) by End User, 2022 to 2032
Figure 18: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 22: North America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 23: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 24: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 25: North America Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 28: North America Market Attractiveness by Disease Indication, 2022 to 2032
Figure 29: North America Market Attractiveness by End User, 2022 to 2032
Figure 30: North America Market Attractiveness by Country, 2022 to 2032
Figure 31: Latin America Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 32: Latin America Market Value (US$ Million) by End User, 2022 to 2032
Figure 33: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 37: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 43: Latin America Market Attractiveness by Disease Indication, 2022 to 2032
Figure 44: Latin America Market Attractiveness by End User, 2022 to 2032
Figure 45: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 46: Europe Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 47: Europe Market Value (US$ Million) by End User, 2022 to 2032
Figure 48: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 52: Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 53: Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 58: Europe Market Attractiveness by Disease Indication, 2022 to 2032
Figure 59: Europe Market Attractiveness by End User, 2022 to 2032
Figure 60: Europe Market Attractiveness by Country, 2022 to 2032
Figure 61: Asia Pacific Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 62: Asia Pacific Market Value (US$ Million) by End User, 2022 to 2032
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 73: Asia Pacific Market Attractiveness by Disease Indication, 2022 to 2032
Figure 74: Asia Pacific Market Attractiveness by End User, 2022 to 2032
Figure 75: Asia Pacific Market Attractiveness by Country, 2022 to 2032
Figure 76: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2022 to 2032
Figure 77: Middle East and Africa Market Value (US$ Million) by End User, 2022 to 2032
Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2022 to 2032
Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032
Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032
Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032
Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by End User, 2017 to 2032
Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by End User, 2022 to 2032
Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by End User, 2022 to 2032
Figure 88: Middle East and Africa Market Attractiveness by Disease Indication, 2022 to 2032
Figure 89: Middle East and Africa Market Attractiveness by End User, 2022 to 2032
Figure 90: Middle East and Africa Market Attractiveness by Country, 2022 to 2032
